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INTRODUCTION
Pyruvate kinase (PYK) catalyses the last step in glycolysis to produce ATP and pyruvate, and in most organisms studied, PYKs have similar homotetrameric architectures with each monomer composed of four domains (Figure 1a) . Four human tissue-specific PYK isoenzymes have been described: HsRPYK (erythrocyte), HsLPYK (liver), HsM1PYK (muscle) and HsM2PYK (embryonic or tumour). The M1 isoform is constitutively active while the other three are allosterically regulated by the effector molecule fructose 1,6-bisphosphate (F16BP) [1] . Trypanosomatid PYKs are distinguished by their use of the chemically distinct molecule fructose 2,6-bisphosphate (F26BP) as the effector, and recently the detailed allosteric mechanism for PYK of the pathogenic protist Leishmania mexicana (LmPYK) has been elucidated [2] .
PYK has been implicated as playing a central role in a number of proliferative and infectious diseases, and the discovery of isoenzyme-specific inhibitors or activators of PYK could be of potential interest in the elucidation of the etiology of cancer [3] and of metabolic diseases such as diabetes and obesity [4] , as well as infectious diseases caused by bacteria [5] , trypanosomatid parasites [6] and the malaria parasites Plasmodium spp. [7] . For example, PYK deficiency in erythrocytes results in nonspherocytic haemolytic anemia and over 130 mutations in HsRPYK have been identified which contribute to the disease [8, 9] . There is also a strong link between the up-regulation of the human M2PYK isoenzyme and oncogenesis [3] , and this isoenzyme is found in all tumours studied to date [3] . The effectorregulated HsM2PYK can facilitate a build-up of phosphometabolites which are required for the cancer cell to proliferate. A number of potent activators of HsM2PYK have been identified with AC 50 values around 30 nM [10] , however the only examples of HsM2PYK inhibitors bind relatively weakly with IC 50 values of 10 to 20 µM [11] .
RNAi knockdown of PYK and other enzymes in the glycolytic pathway in trypanosomatids has facilitated a systems biology approach to elucidate the roles played by these enzymes [12] . A complementary approach to regulate PYK activity by small molecule compounds has been hindered by the lack of appropriate chemical tools. One of the few compounds currently available is the polysulfonated drug suramin, one of the earliest synthetic drugs used to treat human African trypanosomiasis. It is a promiscuous binder with a complex pharmacology and poorly understood mode of action. However, it has been shown to inhibit seven of the ten enzymes in the glycolytic pathway of Trypanosoma brucei [13, 14] . A crystal structure of a complex of LmPYK with suramin shows that it acts as an ATP/ADP mimic and binds competitively with the ADP substrate [15] . Suramin also inhibits all four human isoforms of PYK with K i values between 1 and 20 µM [15] . In addition, affinity labelling of rabbit-muscle PYK has been achieved by covalent modification of active-site residues using nucleotide analogues [16] [17] . The only other known general PYK inhibitor is the substrate analogue oxalate, which exhibits poor specificity and binds with relatively weak affinity (K i = 220 µM) [18] . Selective inhibitors of PYK are needed as biochemical tools for studying the glycolytic pathway and as potential leads for drug development. Here we report the discovery of a novel covalent PYK inhibitor, 4-[(1,1-dioxo-1,2-benzothiazol-3-yl)sulfanyl]benzoic acid (DBS, Figure 1c ).
EXPERIMENTAL Expression and purification of wild-type and Lys335Arg mutant forms of LmPYK
Chemically competent Escherichia coli Rosetta 2 * (DE3)pLysS (Merck -Cat. No. 71403) cells were transformed with either the wild-type or mutated plasmid (see Supplementary data). Both wild-type and Lys335Arg mutant forms of LmPYK were expressed and purified as described previously [15] .
Synthesis and characterization of covalent inhibitors
A series of saccharin derivatives identified as inhibitors of LmPYK by quantitative highthroughput screening (qHTS) was further elaborated by de novo chemical synthesis, purification and characterization. The procedures for the synthesis and purification of compounds NCG00186526, NCGC00059857, NCGC00188411 and NCGC00188636 ( Figure 1c ) and their characterization are described in detail in the Supplementary data. One of these analogues, DBS (NCGC00188636), displayed improved stability and solubility profiles relative to the original screening hit (NCGC00186526) and was therefore used for the experiments described in this paper.
PYK inhibitor assay
The following reagents were added to a 50 mL Falcon tube (equivalent to 11×1 mL assays): 8.58 mL of assay mix (1x assay buffer (50 mM triethanolamine (TEA), pH 7.2, 100 mM potassium chloride, 3 mM magnesium chloride, 10% glycerol), 0.2 mM NADH (128023-Roche), 3.2 U/mL lactate dehydrogenase (Sigma-61309)), 1.6 U/mL LmPYK, 0.4 mM phosphoenolpyruvate (PEP) (Sigma-79430) and 2.20 mL of 250 µM inhibitor solution (made up with 1x assay buffer from a 170 mM stock in 100% DMSO, final conc. 50 µM -added last to the reaction mix). The control reaction mix was made identically except 1x buffer was used in place of the inhibitor solution. Both the control and inhibitor reaction mixtures were incubated throughout the experiment in a 25 °C water bath (prior to the addition of inhibitor which was also incubated at 25 °C). To 990 µL of the reaction mix, 10 µL of 20 mM ADP (final concentration = 0.2 mM ADP (Sigma-A4386); made up with 1x assay buffer) was added to start the reaction. The mixture was gently agitated and the decrease in absorbance at 340 nm was measured for 2 min (using Lambda Bio). The process was repeated every 20 min over 200 min for both the control and inhibitor. The initial rate was then calculated using UV kinlab. The rate for each inhibitor assay was expressed as a percentage of the control assay.
Preparation of inhibitor-modified LmPYK
The DBS inhibitor (Stock = 172 mM in 100% dimethylsulfoxide (DMSO)) was added to 200 µL of LmPYK (10 mg/mL: 184 µM in 20 mM TEA buffer (pH 7.2) and 10% glycerol) to a final concentration of 9 mM (maintaining a similar molar ratio of inhibitor to protein as used in the kinetic assay). The sample was then incubated overnight at 4 °C. Dithiothreitol (DTT) was added to a final concentration of 1 mM, and the LmPYK-DBS inhibitor mix was incubated at room temperature for 15 min. The DTT and leaving group were removed by repeated dilutions (using 20 mM TEA buffer (pH 7.2) and 10% glycerol) and by concentrating the sample in a Vivaspin column (molecular mass cut off = 100 kDa). The sample was concentrated to 12 mg/mL.
Crystallization and data collection
Samples of inhibitor-modified LmPYK (prepared as described) were diluted to 10 mg/mL using a buffer containing 20 mM TEA (pH 7.2) and 1,3,6,8-pyrenetetrasulfonic acid (PTS, final concentration 1 mM). Single crystals of inhibitor-modified LmPYK complexed with PTS were obtained at 4 °C by vapour diffusion using the hanging drop technique. The drops were formed by mixing 1.5 µL of protein solution with 1.5 µL of a well solution, composed of 12 -16% polyethyleneglycol (PEG) 8,000, 20 mM TEA buffer (pH 7.2), 50 mM magnesium chloride, 100 mM potassium chloride and 10% glycerol. The drops were equilibrated against a reservoir filled with 0.5 mL of well solution. Crystals grew to maximum dimensions (1.0×0.2×0.1 mm) after 24 -48 h. Prior to data collection, crystals were equilibrated for 14 h over a well solution composed of 14 -18% PEG 8,000, 20 mM TEA buffer (pH 7.2), 50 mM magnesium chloride, 100 mM potassium chloride and 25% glycerol, which eliminated the appearance of ice rings. Intensity data were collected (φscans were 2° over 180°) at the Diamond synchrotron radiation facility in Oxfordshire, United Kingdom on beamline IO3 from a single crystal cryocooled in liquid nitrogen. A single crystal gave data to a resolution of 2.65 Å at 100 K.
Structure determination and analysis of model geometry
The LmPYK-DBS structure was solved and refined using the method described previously [2] , yielding R/R free values of 21.9/27.35. A further round of TLS restrained refinement (four optimal TLS groups were determined using TLSMD procedure [19] ) yielded final R/ R free values of 22.3/26.6. The geometry of the model was assessed using MolProbity [20] . Although electron density was well defined for Thr296 (a key active-site residue), it exhibits geometry outwith the Ramachandran plot here and in many PYK structures. This is primarily due to a restricted geometry, which facilitates interactions with active-site ligands.
RESULTS AND DISCUSSION

High-throughput screening identified a series of saccharin-based inhibitors
There were 292,740 compounds in the NIH Molecular Libraries-Small Molecule Repository tested in the primary screen for the wild-type LmPYK (PubChem AID 1721). The screen was performed at seven compound concentrations using quantitative high-throughput screening (qHTS) [21, 22] and identified 1,087 high-quality concentration-response curves, corresponding to a hit rate of 0.4% of the library. One of the top actives from this series was the saccharin derivative NCGC00186526, with an IC 50 of 10 µM. The oxo linkage in this compound was labile, and the molecule was found to hydrolyse to saccharin and the corresponding phenol (Figure 1c ). Stable sulphur (NCGC00188411) and nitrogen (NCGC00059857) analogues were prepared ( Figure 1c) and tested in the LmPYK activity assay. Only NCGC00188411 showed inhibitory activity (IC 50 = 5 µM). At this point it was hypothesized that covalent modification of either cysteine or lysine in the enzyme, as well as the leaving group ability of the resultant phenol, thiophenol and aniline explained the trend in activity [23] 
Covalent modification of LmPYK by DBS is confirmed by X-ray crystal structure analysis
LmPYK crystals grown in the presence of 2 mM oxalate and 2.8 mM DBS (LmPYK-OX/ DBS) were anisotropic, and diffracted poorly to approximately 4 Å. Despite the relatively low resolution, difference (F o -F c ) electron density was observed near Lys335 in all active sites (Figure 1b) suggesting that Lys335 was covalently modified by the saccharin moiety (Figure 1d ). Improved quality crystals diffracting to 2.65 Å were obtained using a purification protocol of DBS-modified LmPYK in which DMSO was removed by dilution and PTS was added to the crystallization solution (see Table 1 for data collection and refinement statistics). Electron density corresponding to the covalent addition of the saccharin moiety to Lys335 is clearly visible in all active sites (Figure 1b) . The modified Lys335 residue is located at the adenine-binding site and blocks ADP/ATP binding ( Figure  2a) . Electron density was carefully examined around all other lysines in the structure but no evidence for their covalent modification was observed.
Inhibition of LmPYK by DBS is time dependent
An inhibition assay was used to examine the covalent reaction further, whereby LmPYK activity was monitored over time in the presence of 50 µM DBS (Figure 3d ). Maximal inhibition of ~80% was achieved after ~250 min (Figure 1e , curve A), although LmPYK inhibition never reached 100% inhibition even after 10 h (after prolonged incubation periods at 25 °C both the wild-type and Lys335Arg of LmPYK mutant began to aggregate). The small amount of remaining activity could possibly be due to weak binding of ADP to the DBS-modified active site. The X-ray structure of the modified enzyme suggests that the saccharin group covalently bound to Lys335 with its flexible side chain could adopt conformations that would still allow ADP access to the active site (Figure 2a) , albeit with reduced affinity. In terms of potential antiparasitic activity it is relevant to note that incomplete depletion (about 75%) of the intracellular concentration of PYK by RNAi is sufficient to cause cell death in the pathogenic bloodstream form of T. brucei [24] .
The Lys335Arg mutation confirms the covalent inhibitory mechanism
To test whether inhibition stems from the covalent modification of Lys335 and not modification of other lysine residues in PYK, we expressed and purified the Lys335Arg mutant of LmPYK. The wildtype and Lys335Arg mutant of LmPYK enzymes exhibited similar activity and kinetic parameters (Supplementary Table S1 ). However, on addition of DBS and under identical assay conditions to that of wild-type LmPYK, the Lys335Arg mutant exhibited essentially no change in activity over time (Figure 1e, curve D) .
Evidence of selectivity of DBS for Lys335 is suggested by the inability of DBS to inhibit rabbit lactate dehydrogenase (a coupling enzyme) through covalent modification of a similar active-site lysine, Lys56. This residue is similar in both location (found also on the rim of the active site cleft) and interaction (interacting with the ribose hydroxyl of the nucleoside group of NAD) to Lys335 of LmPYK (Supplementary Figure S3) . A lysine residue (Lys531) also exists in the active site of firefly luciferase (PDB code 2DIT). Both these coupling enzymes provide good controls to suggest that DBS displays selectivity for binding Lys335. The X-ray structural results discussed in the following section provide a rationale for this specificity.
Mechanism of covalent modification by DBS is suggested by the structure of LmPYKsuramin
A series of phenyl sulfonated dye-like molecules including the trypanocidal drug suramin has been shown to bind in a near-identical position within the active site of LmPYK [15] . The LmPYK-DBS monomer was superimposed onto the LmPYK-suramin structure, with excellent alignment of the protein backbones (RMS fit = 0.5 Å). Modelling a fit of the sulfonamide group of the unreacted DBS molecule onto the sulfone group in the suramin complex, perfectly positions Lys335 for nucleophilic attack on C3 of the saccharin ring to release the sulphide moiety (Figures 1d, 2) . The requirement for DBS to dock in such a specific pose could explain its specificity for Lys335 over other lysine residues in the structure. The X-ray structure however suggests that once the covalent bond has formed, the modified lysine adopts a different pose. Comparisons of the relevant X-ray structures show the sulphone groups of suramin and of the saccharin moiety of DBS covalently attached to Lys335 are 4.4 Å apart (Figure 2b and Supplementary Figure S3 ).
DBS is a covalent inhibitor of both human and trypanosomatid PYKs
Lysine 335 is relatively well conserved among different PYK species and it is of interest that naturally occurring mutations in HsRPYK (equivalent residue Lys410) to either glutamic acid [9] or aspartic acid [25] result in non-spherocytic haemolytic anaemia. DBS was found to inhibit both HsRPYK (the human PYK isoenzyme present in erythrocytes) and HsM2PYK (the human PYK isoenzyme present in embryonic and tumour cells) with IC 50 values of 8 µM and 16.3 µM, respectively (see Supplementary Figure S4 ). These values compare with an IC 50 value of DBS for LmPYK of 2.9 µM. Modelled poses of the precleavage DBS binding pocket highlight sequence differences between the trypanosomatid and human enzymes (Figure 2d ) and it is likely that such differences in the saccharin binding pocket provide an opportunity for the design of more potent species-specific inhibitors against either trypanosomatid or human PYK isoforms. Overlay of the X-ray structures of LmPYK (this paper) and the X-ray structure of HsM2PYK showing differences in the amino acid side chains in three regions (R1, R2 R3) around the modified Lys335 (yellow) that could enable the design of isoenzyme-specific families of inhibitors.
